Link Pharma Chem

Who are the top shareholders of the Link Pharma Chem?

The top shareholders of Link Pharma Chem include Rishikesh Satishbhai Thakur with 18.95%, followed by Gurudev Marketing Pvt. Ltd. at 5.76%, and individual investors holding 37.17%. There are no pledged promoter holdings, minimal mutual fund involvement, and no foreign institutional investors.

The top shareholders of Link Pharma Chem include the promoters, with Rishikesh Satishbhai Thakur holding the largest share at 18.95%. The company has no pledged promoter holdings. In terms of public shareholders, Gurudev Marketing Pvt. Ltd. is the highest public shareholder with a stake of 5.76%. Additionally, individual investors collectively hold 37.17% of the shares. Mutual funds have a minimal presence, with only one scheme holding 0.02%, and there are currently no foreign institutional investors (FIIs) involved.

Who are in the management team of Link Pharma Chem?

As of March 2023, the management team of Link Pharma Chem includes S G Thakur (Chairman & Wholetime Director), Rishikesh S. Thakur (Managing Director), and independent directors S B Dhatrak, Devang U Shah, and Rachna Ghai. They are responsible for the company's governance and strategic direction.

As of March 2023, the management team of Link Pharma Chem includes the following individuals:<BR><BR>1. S G Thakur - Chairman & Wholetime Director<BR>2. Rishikesh S. Thakur - Managing Director<BR>3. S B Dhatrak - Independent Director<BR>4. Devang U Shah - Independent Director<BR>5. Rachna Ghai - Independent Director<BR><BR>These members play key roles in the governance and strategic direction of the company.

Has Link Pharma Chem declared dividend?

No Dividend History Available

Who are the peers of the Link Pharma Chem?

Link Pharma Chem's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Vivid Global, Kuwer Industries, Bhagawati Oxygen, and Lime Chemicals. In terms of management risk, GHCL and Chemplast Sanmar are excellent, while Link Pharma Chem has average risk; India Glycols leads in 1-year returns at 150.38%, with Link Pharma Chem at -10.37%.

Peers: The peers of Link Pharma Chem are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Vivid Global, Kuwer Industries, Bhagawati Oxygen, and Lime Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Tata Chemicals, India Glycols, and Link Pharma Chem. Below Average management risk is present at Fischer Medical, Vivid Global, Kuwer Industries, and Lime Chemicals, and Bhagawati Oxygen does not qualify. Growth is below average for Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Link Pharma Chem, Kuwer Industries, and Lime Chemicals, while Fischer Medical and Vivid Global also show average growth. Bhagawati Oxygen and Tulasee Bio-Eth. do not qualify for growth. Capital structure is excellent at GHCL, average at Tata Chemicals and Link Pharma Chem, and below average at Chemplast Sanmar, India Glycols, Fischer Medical, Vivid Global, Kuwer Industries, and Lime Chemicals, with Bhagawati Oxygen and Tulasee Bio-Eth. not qualifying.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.38%, while Lime Chemicals has the lowest at -37.18%. Link Pharma Chem's 1-year return of -10.37% is better than Lime Chemicals but worse than India Glycols. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Lime Chemicals, and Bhagawati Oxygen.

Is Link Pharma Chem overvalued or undervalued?

As of May 28, 2025, Link Pharma Chem is considered risky and overvalued with a negative PE ratio of -15.17 and a year-to-date return of -12.29%, significantly underperforming compared to its peers like Godrej Industries and the Sensex.

As of 28 May 2025, the valuation grade for Link Pharma Chem has moved from very attractive to risky. The company is currently assessed as overvalued, given its negative PE ratio of -15.17, an EV to EBITDA of 22.01, and a ROE of -7.51%. These ratios indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Link Pharma Chem's valuation metrics starkly contrast with those of Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, indicating a more favorable market position. Additionally, Solar Industries is deemed very expensive with a PE ratio of 123.77, highlighting the disparity in valuation within the sector. Despite a recent uptick in stock price, Link Pharma Chem's year-to-date return of -12.29% significantly underperforms the Sensex's 5.66%, reinforcing the notion of its overvaluation.

What is the technical trend for Link Pharma Chem?

As of June 5, 2025, Link Pharma Chem's trend has shifted to bearish, supported by bearish indicators from moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST.

As of 5 June 2025, the technical trend for Link Pharma Chem has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD indicates a bearish trend. Both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages are also bearish, reinforcing the negative sentiment. The KST shows a mildly bullish signal on the weekly chart, but is bearish on the monthly, indicating mixed signals. Overall, the lack of clear trends in Dow Theory further supports a bearish perspective.

What does Link Pharma Chem do?

Link Pharma Chem Ltd is a mid-sized chemical manufacturing company specializing in commodity chemicals, primarily thionil chloride. As of March 2025, it reported net sales of 64 Cr and a net loss of 4 Cr, with a market cap of INR 16 Cr.

Overview:<BR>Link Pharma Chem Ltd is a mid-size leading chemical manufacturing company operating in the commodity chemicals industry, categorized as a micro-cap.<BR><BR>History:<BR>The company was incorporated in 1986 and has undergone several capacity expansions, increasing its production of thionil chloride from 300 tpa to 2100 tpa by 1994. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 64 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -4 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 16 Cr (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.47 <BR>Return on Equity: -7.51% <BR>Price to Book: 1.14 <BR><BR>Contact Details:<BR>Address: 162, GIDC Ind Estate Nandesari Vadodara Gujarat : 391340 <BR>Tel: 91-0265-3065000/2840448/3093931 <BR>Email: linkpharmacs@gmail.com <BR>Website: http://www.linkpharmachem.co.in

How big is Link Pharma Chem?

As of 24th July, Link Pharma Chem Ltd has a market capitalization of 16.00 Cr and reported Net Sales of 25.44 Cr with a Net Profit loss of 1.03 Cr for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 13.71 Cr and Total Assets of 25.95 Cr.

As of 24th July, Link Pharma Chem Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 25.44 Cr. However, it experienced a loss of 1.03 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 13.71 Cr and Total Assets amounting to 25.95 Cr.

When is the next results date for Link Pharma Chem?

Link Pharma Chem will announce its results on 13 November 2025.

Link Pharma Chem is scheduled to declare its results on 13 November 2025.

How has been the historical performance of Link Pharma Chem?

Link Pharma Chem has experienced a significant decline in net sales and profitability, with losses reported in the most recent fiscal year. Net sales dropped from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, and the company reported a profit after tax loss of -1.03 Cr in March 2025.

Answer:<BR>The historical performance of Link Pharma Chem shows a declining trend in net sales and profitability over the past few years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Link Pharma Chem's net sales have decreased from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, reflecting a significant decline. The total operating income followed a similar trend, dropping from 53.56 Cr in March 2022 to 25.43 Cr in March 2025. The company's total expenditure also decreased, but not as sharply, leading to operating profits that turned negative in March 2024 and remained low at 0.31 Cr in March 2025. Profit before tax has been negative since March 2024, with a loss of 1.40 Cr reported in March 2025. Consequently, the profit after tax also showed losses, amounting to -1.03 Cr in March 2025. The company's total assets decreased from 32.46 Cr in March 2023 to 23.06 Cr in March 2025, while total liabilities also fell from 25.95 Cr to 23.06 Cr in the same period. Cash flow from operating activities was positive at 2.00 Cr in March 2025, but the overall cash position remained stagnant, with no cash inflow or outflow reported. Overall, Link Pharma Chem has faced significant challenges, leading to declining revenues and profitability over the years.

Are Link Pharma Chem Ltd latest results good or bad?

Link Pharma Chem Ltd's latest results are concerning, showing a 95% decline in net profit despite a 31.04% revenue increase, with operating margins dropping significantly. The company's low Mojo Score of 12 indicates weak fundamentals, categorizing it as a "Strong Sell."

Link Pharma Chem Ltd's latest results indicate significant challenges and are generally viewed as bad. In the second quarter of FY26, the company reported a drastic 95% decline in net profit, dropping to just ₹0.02 crores from ₹0.40 crores in the previous quarter. This sharp decrease in profitability occurred despite a year-on-year revenue growth of 31.04%, highlighting severe operational issues.<BR><BR>Operating margins also collapsed to 5.41%, down from 8.19% in the previous quarter, reflecting increasing cost pressures and a lack of pricing power. The company's profit after tax margin shrank to a mere 0.32%, indicating that it is struggling to manage costs effectively.<BR><BR>Moreover, Link Pharma Chem's proprietary Mojo Score stands at a low 12 out of 100, categorizing it in "Strong Sell" territory, which underscores the weak fundamentals and operational difficulties it faces. Overall, the results suggest that the company is experiencing a profitability crisis, making the outlook concerning for investors.

Should I buy, sell or hold Link Pharma Chem Ltd?

Why is Link Pharma Chem Ltd falling/rising?

As of 04-Mar, Link Pharma Chem Ltd's stock price is at 27.00, down 2.63%, and has significantly underperformed the benchmark with a -23.92% return over the past year. Despite some growth in net sales, the company's long-term fundamentals are weak, contributing to its bearish trend and stock decline.

As of 04-Mar, Link Pharma Chem Ltd's stock price is falling, currently at 27.00, reflecting a change of -0.73 or -2.63%. The stock has underperformed against the benchmark, with a performance today that is 2.1% lower than its sector. Additionally, it is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend.<BR><BR>Over the past year, the stock has generated a return of -23.92%, significantly underperforming the Sensex, which has increased by 8.39%. This consistent underperformance is further highlighted by a -34.61% return over the last three years compared to a +32.28% return for the benchmark. <BR><BR>Despite some positive financial indicators, such as a 28.40% growth in net sales and a higher profit after tax, the long-term fundamentals appear weak. The company has experienced a -27.15% compound annual growth rate in operating profits over the last five years and has a poor EBIT to interest ratio of 0.68, indicating challenges in servicing its debt. These factors contribute to a perception of weak profitability and have led to the stock's decline.

Which are the latest news on Link Pharma Chem?